Noe LGA Gesundheit Region Mitte GmbH

The medical center is at the forefront of research in Multiple Myeloma, focusing on innovative treatment regimens that enhance patient outcomes. The center's studies explore the efficacy of novel drug combinations and maintenance therapies to improve progression-free survival and achieve minimal residual disease negativity.

• Elotuzumab and Carfilzomib Combinations
• Isatuximab with Lenalidomide-Dexamethasone
• Relapsed or Refractory Myeloma Therapies

These efforts contribute significantly to the development of personalized treatment plans, offering hope for improved quality of life and survival rates in patients with newly diagnosed and relapsed myeloma.

Specializing in Dupuytren's Contracture, the center is pioneering the use of bacterial collagenase to address this condition. The research aims to establish the safety and efficacy of this treatment, potentially offering a less invasive alternative to surgical intervention.

• Collagenase Injection Therapy
• Phase I/II Safety and Efficacy Studies

By advancing these therapeutic options, the center is enhancing the management of Dupuytren's Contracture, aiming to improve hand function and patient satisfaction.

The center is a leader in the treatment of Large B-Cell Lymphoma, investigating cutting-edge therapies such as CAR T-cell treatments and novel antibody-drug conjugates. These studies focus on improving event-free survival and overall treatment efficacy.

• Axicabtagene Ciloleucel Therapy
• Polatuzumab Vedotin and Glofitamab Combinations

Through these innovative approaches, the center is setting new standards in the treatment of high-risk and relapsed lymphoma, offering patients more effective and targeted therapeutic options.

Focusing on pediatric Asthma, the center is evaluating the efficacy of novel inhalation therapies to improve lung function in young patients. This research is crucial in developing age-appropriate treatments that enhance quality of life and disease management.

• Indacaterol and Mometasone Combinations
• Comparative Studies with Budesonide

These studies aim to provide safer and more effective asthma management strategies for children, reducing the burden of this chronic condition.

The center is advancing the treatment of Chronic Lymphocytic Leukemia through innovative drug combinations that target disease recurrence. The focus is on improving overall response rates and extending remission periods.

• Venetoclax and Obinutuzumab Combinations
• Retreatment Efficacy Studies

By refining these therapeutic approaches, the center is enhancing the standard of care for patients with recurrent leukemia, aiming for longer-lasting remissions and improved survival outcomes.

Specializing in inflammatory bowel diseases, the center is conducting pivotal research on Ulcerative Colitis and Crohn's Disease. The focus is on novel biologic therapies that aim to induce clinical remission and improve endoscopic outcomes.

• TEV-48574 Efficacy Studies
• GS-5290 Clinical Response Trials

These efforts are crucial in developing more effective treatments that address the underlying inflammation and improve the quality of life for patients with these chronic conditions.

The center is at the forefront of research in Chronic Kidney Disease, focusing on innovative therapies that reduce albuminuria and slow disease progression. The studies aim to improve renal outcomes and patient quality of life.

• Balcinrenone and Dapagliflozin Combinations
• Pharmacokinetics of Cefepime in Dialysis

Through these research initiatives, the center is contributing to the development of more effective treatment protocols for patients with chronic kidney conditions.

Focusing on Non-Alcoholic Steatohepatitis, the center is exploring the efficacy of novel oral therapies to resolve liver inflammation and fibrosis. The research aims to halt disease progression and improve liver health.

• Resmetirom Efficacy Trials
• Histological Improvement Studies

These studies are pivotal in developing effective treatments for NASH, offering hope for patients with this progressive liver disease.

The center is pioneering research in Breast Cancer, focusing on neoadjuvant therapies that enhance treatment efficacy and improve survival rates. The studies aim to optimize therapeutic regimens for high-risk and locally advanced cases.

• Atezolizumab, Pertuzumab, and Trastuzumab Combinations
• Event-Free Survival Comparisons

Through these innovative approaches, the center is advancing the treatment landscape for breast cancer, offering patients more effective and personalized care options.

Specializing in Congestive Heart Failure, the center is evaluating the potential of gene therapy to improve cardiac function and patient outcomes. The research focuses on innovative delivery methods and therapeutic efficacy.

• AB-1002 Gene Therapy Trials
• Safety and Efficacy Assessments

These studies are crucial in developing groundbreaking treatments for heart failure, aiming to enhance quality of life and extend survival for affected patients.